Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1

Conditions

Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Sezary Syndrome 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pathological Conditions, Signs and Symptoms 1Pathologic Processes 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Meningeal Carcinomatosis 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Processes × Pemetrexed × Other neoplasm × Clear all
NCT00692159 2010-09-10

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Tracon Pharmaceuticals Inc.

Phase 1 Completed
28 enrolled
Other neoplasm

Neoplasms, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡